Dissecting the Decision: Investigators Discuss Available Research Data and Clinical Factors That Shape the Management of HER2-Positive Breast CancerTARGET AUDIENCE OVERVIEW OF ACTIVITY However, considerable gaps remain in optimizing treatment of this disease subtype, particularly with the growing armamentarium of effective HER2-targeted agents. In the treatment of early-stage HER2-positive breast cancer several issues remain incompletely elucidated, including who should receive neoadjuvant versus adjuvant therapy, the use of single versus dual anti-HER2 blockade, the use of anthracycline- versus nonanthracyline-containing chemotherapy and the approach to therapy for patients with small, node-negative disease. In the advanced disease setting several clinical questions remain open, including the optimal sequencing of treatments in the first, second and later lines of treatment, the timing and duration of treatment, how previous adjuvant HER2-targeted therapy influences treatment decision-making, how hormone receptor status can affect therapeutic options and how best to manage brain metastases, which occur in approximately 50% of patients with metastatic HER2-positive disease. In addition to the preceding issues, HER2 test results are discordant between primary and metastatic disease for 5% to 10% of patients, necessitating management approaches that may have a significant impact on treatment. By providing access to the latest research developments and expert perspectives on the treatment of HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings, these proceedings from a case-based CME symposium held at the 2014 ASCO Annual Meeting aim to assist medical oncologists, breast surgeons and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Harold J Burstein, MD, PhD No real or apparent conflicts of interest to disclose. Edith A Perez, MD No real or apparent conflicts of interest to disclose. Kimberly L Blackwell, MD Advisory Committee: Amgen Inc, Roche Laboratories Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Contracted Research: Celgene Corporation, Genentech BioOncology; Speakers Bureau: Genomic Health Inc. Mark D Pegram, MD Consulting Agreements: Celgene Corporation, Cepheid, Genentech BioOncology, Shionogi Inc. Fabrice André, MD, PhD Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation; Contracted Research: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation. CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Patricia A DeFusco, MD Contracted Research: Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc. Leon H Dragon, MD No real or apparent conflicts of interest to disclose. Bonni L Guerin, MD Speakers Bureau: Celgene Corporation, Genomic Health Inc. Carolyn B Hendricks, MD No real or apparent conflicts of interest to disclose. Kert D Sabbath, MD No real or apparent conflicts of interest to disclose. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. This activity is supported by an educational grant from Genentech BioOncology. Hardware/Software Requirements: Last review date: September 2014 |